LumaBridge (formerly Cancer Insight) has penned a new partnership with the Parker Institute for Cancer Immunotherapy (PICI) to develop new immunotherapies.
The collaboration aims to give PICI Affiliated Partners—made up of PICI’s network of institutions and investigators, affiliated companies and nonprofit organizations—direct access to LumaBridge’s CRO services. Those offerings include clinical trial design as well as regulatory strategy support from patient accrual on through to quality assurance, data management, pharmacovigilance and other services.
Financial terms of the deal weren’t disclosed.
"By combining our focus with additional expertise in clinical trial design and oversight, we aim to streamline the development process and ultimately accelerate novel immunotherapies to patients,” Ute Dugan, M.D., Ph.D., chief medical officer of PICI, said in a statement.
San Francisco-based PICI’s research strategy targets challenges such as overcoming resistance to checkpoint inhibitors and identifying and expanding partnerships between the institute and biopharma companies.
LumaBridge, which is based in San Antonio, focuses on accelerating development of immunological cures for cancer by leveraging innovative science, advanced technologies and new modes of research collaboration.